We are monitoring the impact of COVID-19 & Recession alarm on APAC Psoriasis Drugs Market Get in touch with us for detailed analysis Know More
Share on

Asia Pacific Psoriasis Drugs Market Research Report - Segmented By Drug Type, Route of Administration, Target, & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - industry Analysis on Size, Share, Trends and Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 1638
Pages: 140

APAC Psoriasis Drugs Market Size (2022 to 2027)

The size of the Asia Pacific Psoriasis Drugs Market has been calculated at USD 1.19 billion in 2022 and is expected to grow USD 1.77 billion by 2027, registering a CAGR of 8.24% from 2022 to 2027.

Psoriasis is a chronic inflammatory skin condition that affects about 2% of the population. Immunologic, genetic, and environmental variables play a role in psoriasis, while the exact cause is unknown. Topical medicines, systemic therapy, and biologic therapies are part of the current marketed pharmacological landscape for psoriasis. In recent years, additional immunological components have been discovered, and greater knowledge of psoriasis has led to new biological therapies targeting particular immunological factors that cause psoriasis.

Y-O-Y growth in the aging population in APAC, rising number of product launches, growing awareness initiatives, and the increasing number of psoriasis patients are some of the primary drivers driving the APAC psoriasis medications market forward. People are becoming more aware of psoriasis and its therapies, leading to a growing need for effective psoriasis medications. According to the World Health Organization, psoriasis can strike at any age, although according to certain research, psoriasis begins to emerge at the age of 33. However, according to some studies, the disease strikes people before they reach the age of 46.

Despite the expanding improvements in the psoriasis drugs market, the high cost of these drugs is expected to constitute a stumbling block to market expansion. Furthermore, psoriasis drugs may cause side effects such as high blood pressure, liver damage, and kidney damage, which are expected to limit the market's growth over the forecast period.

This research report on the Asia Pacific psoriasis drugs market has been segmented and sub-segmented into the following categories:

By Drug Type:

  • Pharmaceuticals
  • Biopharmaceuticals

By Route of Administration: 

  • Topical
  • Systemic
    • Oral
    • Intravenous
    • Others

By Target: 

  • Tumour Necrosis Factor (TNF)
  • Phosphodiesterase Type 4 (PDE4)
  • Interleukin

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia-Pacific (APAC) region is estimated to be the fastest-growing region in the global psoriasis drugs market during the forecast period. Factors such as rising skin disease incidence, rising disposable income, which leads to increased spending on skincare goods, including psoriasis pharmaceuticals, strong presence of important market players, improved healthcare infrastructure, and quick launch of new medications in the region, are expected to support the psoriasis drugs market during the forecast period.

Countries such as India, China, and Japan are increasing their spending on research and development operations in both developed and developing countries, which is expected to boost the market growth.


Companies playing a notable role in the APAC Psoriasis Drugs Market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Pfizer Inc (USA), Merck, and Co. Inc (USA), Celgene Corporation (USA), Janssen Biotech Inc (USA), Stiefel Laboratories Inc (USA), Takeda Pharmaceutical Company Limited (Japan), Amgen (USA), and AbbVie (USA).


                1.1 Market Definition      

                1.2 Study Deliverables    

                1.3 Base Currency, Base Year and Forecast Periods            

                1.4 General Study Assumptions  

2. Research Methodology                             

                2.1 Introduction                 

                2.2 Research Phases        

  2.2.1 Secondary Research                           

  2.2.2 Primary Research                 

  2.2.3 Econometric Modelling                      

  2.2.4 Expert Validation                  

                2.3 Analysis Design           

                2.4 Study Timeline            

3. Overview                         

                3.1 Executive Summary  

                3.2 Key Inferences           

                3.3 Epidemology                

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                      

                4.1 Market Drivers            

                4.2 Market Restraints      

                4.3 Key Challenges           

                4.4 Current Opportunities in the Market                

5. Market Segmentation  

                5.1 Drug Type     

                                5.1.1 Introduction                           

  5.1.2 Pharmaceuticals                   

  5.1.3 Biopharmaceuticals                             

  5.1.4  Y-o-Y Growth Analysis, By Drug Type                          

  5.1.5  Market Attractiveness Analysis, By Drug Type                        

  5.1.6  Market Share Analysis, By Drug Type                         

                5.2 Route of Administration         

  5.2.1 Introduction                           

  5.2.2 Topical                      

  5.2.3 Systemic               Oral Intravenous Other

  5.2.4  Y-o-Y Growth Analysis, By Route of Administration

  5.2.5  Market Attractiveness Analysis, By Route of Administration                            

  5.2.6  Market Share Analysis, By Route of Administration                             

                5.3 Target             

  5.3.1 Introduction                           

  5.3.2 Tumour Necrosis Factor (TNF)                        

  5.3.3 Phosphodiesterase Type 4 (PDE4)                

  5.3.4 Interleukin

  5.3.5 Others                      

  5.3.6  Y-o-Y Growth Analysis, By Target                 

  5.3.7  Market Attractiveness Analysis, By Target

  5.3.8  Market Share Analysis, By Target                 

6. Geographical Analysis  

                6.1 Introduction                 

  6.1.1 Regional Trends                    

                                6.1.2 Impact Analysis                     

  6.1.3 Y-o-Y Growth Analysis                        

         By Geographical Area     

         By Product           

         By Type 

         By Application    

         By Indication       

  6.1.4  Market Attractiveness Analysis                     

         By Geographical Area     

         By Product           

         By Type 

         By Application    

         By Indication       

  6.1.5  Market Share Analysis                      

         By Geographical Area     

         By Product           

         By Type 

         By Application    

         By Indication       

                6.2 China               

                6.3 India                

                6.4 Japan              

                6.5 South Korea                 

                6.6 Australia        

7.Strategic Analysis                          

                7.1 PESTLE analysis           

  7.1.1 Political                     

  7.1.2 Economic                 

  7.1.3 Social                         

  7.1.4 Technological                         

  7.1.5 Legal                          

  7.1.6 Environmental                       

                7.2 Porter’s Five analysis                

  7.2.1 Bargaining Power of Suppliers                        

  7.2.2 Bargaining Power of Consumers                    

  7.2.3 Threat of New Entrants                     

  7.2.4 Threat of Substitute Products and Services

  7.2.5 Competitive Rivalry within the Industry                     

8.Market Leaders' Analysis                           

                8.1 Johnson & Johnson   

  8.1.1 Overview                 

  8.1.2 Product Analysis                   

  8.1.3 Financial analysis                  

  8.1.4 Recent Developments                       

  8.1.5 SWOT analysis                       

  8.1.6 Analyst View                          

                8.2 Novartis International AG      

                8.3 Pfizer Inc       

                8.4 Merck and Co. Inc      

                8.5 Celgene Corporation                

                8.6 Janssen Biotech Inc                   

                8.7 Stiefel Laboratories Inc            

                8.8 Takeda Pharmaceutical Company Limited       

                8.9 Amgen           

                8.10 AbbVie         

9.Competitive Landscape

                9.1 Market share analysis              

                9.2 Merger and Acquisition Analysis         

                9.3 Agreements, collaborations and Joint Ventures           

                9.4 New Product Launches           

10.Market Outlook and Investment Opportunities                            


                a) List of Tables  

                b) List of Figures                

  1. Asia-Pacific Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  2. Asia-Pacific Oral Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  3. Asia-Pacific Intravenous Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  4. Asia-Pacific Others Systemic Route Market, By Region, From 2022 - 2027 (USD Billion)
  5. Japan Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  6. China Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  7. India Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)
  8. Australia Psoriasis Drugs Market, By Systemic, From 2022 - 2027 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports




pdf excel


pdf excel powerbi




What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.

Talk to our analyst and get customised report done according to your research needs


Check if you can avail any discount. Submit your details and our team will get back to you.


Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?

Find it too expensive?

Click for Request Sample